

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
18 July 2024 (18.07.2024)



(10) International Publication Number
WO 2024/151638 A2

- (51) **International Patent Classification:**
C07D 487/04 (2006.01) C07D 471/04 (2006.01)
- (21) **International Application Number:**
PCT/US2024/010888
- (22) **International Filing Date:**
09 January 2024 (09.01.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/479,292 10 January 2023 (10.01.2023) US
63/516,701 31 July 2023 (31.07.2023) US
- (71) **Applicant:** **COGENT BIOSCIENCES, INC.** [US/US];
275 Wyman Street, 3rd Floor, Waltham, Massachusetts
02451 (US).
- (72) **Inventors:** **FELL, Jay Bradford**; c/o Cogent Biosciences,
Inc., 4840 Pearl E Circle, Suite 100, Boulder, Colorado
80301 (US). **ROBINSON, John E.**; c/o Cogent Bio-
sciences, Inc., 4840 Pearl E Circle, Suite 100, Boulder, Col-
orado 80301 (US). **FISCHER, John P.**; c/o Cogent Bio-
sciences, Inc., 4840 Pearl E Circle, Suite 100, Boulder,
Colorado 80301 (US). **VINE, Logan E.**; c/o Cogent Bio-
sciences, Inc., 4840 Pearl E Circle, Suite 100, Boulder, Col-
orado 80301 (US). **RODRIGUEZ, Martha E.**; c/o Cogent
Biosciences, Inc., 4840 Pearl E Circle, Suite 100, Boul-
der, Colorado 80301 (US). **FULTON, Jennifer**; c/o Cogent
Biosciences, Inc., 4840 Pearl E Circle, Suite 100, Boulder,
Colorado 80301 (US). **BETTENDORF, Tanna**; c/o Co-
gent Biosciences, Inc., 4840 Pearl E Circle, Suite 100, Boul-
der, Colorado 80301 (US). **NEWHOUSE, Bradley J.**; c/
o Cogent Biosciences, Inc., 4840 Pearl E Circle, Suite 100,
Boulder, Colorado 80301 (US). **RIEGER, Robert A.**; c/o
Cogent Biosciences, Inc., 4840 Pearl E Circle, Suite 100,
Boulder, Colorado 80301 (US). **MALINKY, Cori A.**; c/o
Cogent Biosciences, Inc., 4840 Pearl E Circle, Suite 100,
Boulder, Colorado 80301 (US). **SMITH, Aaron Christo-**


pher; c/o Cogent Biosciences, Inc., 4840 Pearl E Circle,
Suite 100, Boulder, Colorado 80301 (US). **SCAGGS, Toya
D.**; c/o Cogent Biosciences, Inc., 4840 Pearl E Circle, Suite
100, Boulder, Colorado 80301 (US). **DAHLKE, Joshua**;
c/o Cogent Biosciences, Inc., 4840 Pearl E Circle, Suite
100, Boulder, Colorado 80301 (US). **JALLURI, Ravi Ku-
mar**; c/o Cogent Biosciences, Inc., 4840 Pearl E Circle,
Suite 100, Boulder, Colorado 80301 (US). **CHICARELLI,
Mark Joseph**; c/o Cogent Biosciences, Inc., 4840 Pearl E
Circle, Suite 100, Boulder, Colorado 80301 (US). **SALI-
TURO, Leah J.**; c/o Cogent Biosciences, Inc., 4840 Pearl E
Circle, Suite 100, Boulder, Colorado 80301 (US). **MEJIA,
Macedonio J.**; c/o Cogent Biosciences, Inc., 4840 Pearl E
Circle, Suite 100, Boulder, Colorado 80301 (US). **CHAT-
TERJEE, Payal**; c/o Cogent Biosciences, Inc., 4840 Pearl
E Circle, Suite 100, Boulder, Colorado 80301 (US).

(74) **Agent:** **SIEKMAN, Michael** et al.; c/o McDermott Will
& Emery LLP, 200 Clarendon Street, 58th Floor, Boston,
02116-5021 (US).

(81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) **Title:** COMPOUNDS FOR FGFRS INHIBITORS



(57) **Abstract:** A compound having the following structure of Formula (I): (I) or a stereoisomer, salt, or tautomer thereof, wherein R^1 , R^2 , R^5 , A, B, X, and Y are as defined herein. Pharmaceutical composition comprising the compounds, and their use in methods of treating diseases are also described.

WO 2024/151638 A2

[Continued on next page]

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*